欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
YM-358 potassium hydrate_161800-08-4_产品详情
161800-08-4
  • YM-358 potassium hydrate

  • names:

    potassium 5-(4'-((2,7-diethyl-5H-pyrazolo[1,5-b][1,2,4]triazol-5-yl)methyl)-[1,1'-biphenyl]-2-yl)tetrazol-2-ide hydrate

  • CAS号:

    161800-08-4

    MDL Number:
  • MF(分子式): C22H23KN8O MW(分子量): 454.5793
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
YM-358 potassium hydrate
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名 potassium 5-(4'-((2,7-diethyl-5H-pyrazolo[1,5-b][1,2,4]triazol-5-yl)methyl)-[1,1'-biphenyl]-2-yl)tetrazol-2-ide hydrate
英文别名 YM-358 potassium hydrate; YM-358; YM 358; YM358.
CAS号 161800-08-4
Inchi InChI=1S/C22H21N8.K.H2O/c1-3-16-14-29(30-22(16)23-20(4-2)26-30)13-15-9-11-17(12-10-15)18-7-5-6-8-19(18)21-24-27-28-25-21;;/h5-12,14H,3-4,13H2,1-2H3;;1H2/q-1;+1;
InchiKey OVKAVHGXKQGOMJ-UHFFFAOYSA-N
分子式 Formula C22H23KN8O
分子量 Molecular Weight 454.5793
溶解度Solubility
性状 Solid powder
储藏条件 Storage conditions Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).
产品说明 YM-358 potassium hydrate(CAS:161800-08-4 ):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。
IntroductionYM-358 potassium hydrate is a angiotensin type 1 receptor antagonist potentially for the treatment of hypertension and chronic heart. YM358 is both orally active and long-lasting. YM358 has higher efficacy than enalapril for the treatment of hypertension.
Application1
Application2
Application3
警示图
危险性 Warning
危险性警示
安全声明
安全防护
备注
[1]Oka-Akagi T, Fujimori A, Shibasaki M, Matsuda-Satoh Y, Inagaki O, Yanagisawa I. Effects of angiotensin II type 1 receptor antagonist, YM358, on cardiac hypertrophy and dysfunction after myocardial infarction in rats. Biol Pharm Bull. 2002 Jul;25(7):857-60. PubMed PMID: 12132657.
[2]Tokioka-Akagi T, Fujimori A, Shibasaki M, Inagaki O, Yanagisawa I. Comparison of the angiotensin II type 1-receptor antagonist YM358 and the angiotensin-converting enzyme inhibitor enalapril in rats with cardiac volume overload. Jpn J Pharmacol. 2001 May;86(1):79-85. PubMed PMID: 11430476.
[3] Tokioka T, Shibasaki M, Fujimori A, Matsuda-Satoh Y, Uchida W, Inagaki O, Yanagisawa I. Effects of YM358, an angiotensin II type 1 (AT1) receptor antagonist, and enalapril on blood pressure and vasoconstriction in two renal hypertension models. Biol Pharm Bull. 2000 Feb;23(2):174-81. PubMed PMID: 10706380.
[4] Sekine T, Kusano H, Nishimaru K, Tanaka Y, Tanaka H, Shigenobu K. Developmental conversion of inotropism by endothelin I and angiotensin II from positive to negative in mice. Eur J Pharmacol. 1999 Jun 25;374(3):411-5. PubMed PMID: 10422785.
[5] Okazaki T, Suga A, Watanabe T, Kikuchi K, Kurihara H, Shibasaki M, Fujimori A, Inagaki O, Yanagisawa U. Studies on nonpeptide angiotensin II receptor antagonists. I. Synthesis and biological evaluation of pyrazolo[1,5-b][1,2,4]triazole derivatives with alkyl substituents. Chem Pharm Bull (Tokyo). 1998 Jan;46(1):69-78. PubMed PMID: 9468638.
6: Shibasaki M, Fujimori A, Kusayama T, Tokioka T, Satoh Y, Okazaki T, Uchida W, Inagaki O, Yanagisawa I. Antihypertensive activity of a nonpeptide angiotensin II receptor antagonist, YM358, in rats and dogs. Eur J Pharmacol. 1997 Sep 24;335(2-3):175-84. PubMed PMID: 9369371.7: Shibasaki M, Fujimori A, Takanashi M, Kusayama T, Tokioka T, Satoh Y, Okazaki T, Uchida W, Inagaki O, Yanagisawa I. Pharmacological profile of YM358, a novel nonpeptide angiotensin AT1 receptor antagonist. Eur J Pharmacol. 1997 Sep 24;335(2-3):167-73. PubMed PMID: 9369370.8: Yamaguchi N, Fujimoto K, Fujii T, Suzuki T, Kawashima K. Antihypertensive effect of repeatedly administered YM358, an angiotensin AT1-receptor antagonist, in stroke-prone spontaneously hypertensive rats. Jpn J Pharmacol. 1997 Jan;73(1):83-91. PubMed PMID: 9032137.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents